A multi-center, open-label study of CP-690,550 in subjects with moderate to severe ulcerative colitis To assess the safety and tolerability of long-term tofacitinib therapy in subjects with UC.

• Country None
• organs None
• Specialty None

A study of oral CP-690,550 as an induction therapy in subjects with moderate to severe ulcerative colitis To demonstrate the efficacy of tofacitinib in inducing remission in subjects with moderately to severely active UC.

• Country None
• organs None
• Specialty None

A study to investigate the efficacy of CP-690,550 in subjects with moderate to severe ulcerative colitis To demonstrate the efficacy of CP 690,550 in inducing remission in subjects with moderately to severely active ulcerative colitis.

• Country None
• organs None
• Specialty None

A study of oral CP-690,550 as a maintenance therapy in subjects with ulcerative colitis To demonstrate the efficacy of tofacitinib as maintenance therapy in subjects with UC.

• Country None
• organs None
• Specialty None

Persistence of antibodies after meningococcal vaccine PF-06866681 in healthy children Immunogenicity Persistence At 2, 3, 4, 5, 6 years after booster vaccination of children with MenACWY-TT or Meningitec •To evaluate the persistence of meningococcal antibodies in terms of the perce...

• Country None
• organs None
• Specialty None

To evaluate the safety and immunogenicity of a booster dose of meningococcal vaccine administered 10 years after primary vaccination of 1-10 year old subjects with MenACWY-TT (PF-06866681), Meningitec or Mencevax ACWY •To evaluate the long-term persistence of the serum bactericidal (antibody) titres induced by MenACWY-TT vaccine as compared to Meningitec when administered to individuals 1-<2 years of age in terms o...

• Country None
• organs None
• Specialty None